In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biogen Idec Charts A New Course

Executive Summary

Thanks to a November restructuring that refocused the company around its historic strength in neurology and the hiring of two critical executives, Biogen believes it can grow beyond its warhorses Avonex and Tysabri

Related Content

In Seeking Focus, Ipsen Turns To Specialty Pharma Model
Your First Drug's Approved and Launched...Now What?
Surveying The Changing Multiple Sclerosis Landscape
Launching Ampyra: The Long Road To Approval
Launching Ampyra: What Drug Companies Can Learn From The Experience
Bristol Bid For ZymoGenetics Looks Even Better In Light Of Promising Melanoma Data
Biogen Idec Taps Exelixis' Scangos To Be New CEO
Infinity/Purdue: The Challenge of Reprising Roche/Genentech
Deal Update: Taking Stock of Biogen Idec
Biogen Idec: A Sign of Biotech's Maturation


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts